


Exenatide twice daily deemed efficacious across BMI ranges

11 April 2016



groups, significant weight loss occurred with exenatide ($P < 0.0001$); weight increased with both comparators. Exenatide correlated with greater achievement of HbA1c

(HealthDay)—For patients with type 2 diabetes, exenatide twice daily added to insulin glargine is efficacious across body mass index (BMI) ranges, according to a study published online March 29 in *Diabetes, Obesity and Metabolism*.

Bruce H.R. Wolffenbuttel, M.D., Ph.D., from the University of Groningen in the Netherlands, and colleagues examined the correlation between BMI ranges and treatment effects of exenatide twice daily among [patients](#) with type 2 diabetes. In two 30-week studies, patients received exenatide in addition to [insulin glargine](#) (exenatide versus [insulin](#) lispro: 627 patients; and exenatide versus placebo: 259 patients).

The researchers observed no correlation for baseline BMI with changes in efficacy parameters. Significant and similar reductions were seen in hemoglobin A1c (HbA1c; $P < 0.0001$) across BMI range groups in the lispro-comparator study; in the placebo-controlled study, HbA1c reductions were greater for exenatide versus placebo. Across BMI

APA citation: Exenatide twice daily deemed efficacious across BMI ranges (2016, April 11) retrieved 26 September 2022 from <https://medicalxpress.com/news/2016-04-exenatide-daily-deemed-efficacious-bmi.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.